SCM
XFOR icon

Sio Capital Management’s X4 Pharmaceuticals XFOR Stock Holding History

Sio Capital Management’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-43,450
Closed -$872K – 60
2024
Q3 		$872K Sell
43,450
-39,877
-48% -$832K 0.35% 27
2024
Q2 		$1.45M Sell
83,327
-36,287
-30% -$1.19M 0.39% 35
2024
Q1 		$4.99M Hold
119,614
– – 1.49% 24
2023
Q4 		$3.01M Buy
119,614
+32,981
+38% +$802K 0.69% 22
2023
Q3 		$2.83M Buy
86,633
+28,333
+49% +$1.24M 0.88% 31
2023
Q2 		$3.39M Buy
+58,300
New +$3M 0.86% 25
2023
Q1 		– Sell
-60,865
Closed -$1.81M – 57
2022
Q4 		$1.81M Buy
60,865
+13,583
+29% +$643K 0.67% 25
2022
Q3 		$2.43M Buy
47,282
+38,052
+412% +$1.31M 0.77% 23
2022
Q2 		$267K Hold
9,230
– – 0.1% 54
2022
Q1 		$485K Hold
9,230
– – 0.16% 52
2021
Q4 		$634K Sell
9,230
-17,590
-66% -$2.23M 0.19% 61
2021
Q3 		$4.26M Hold
26,820
– – 1.36% 23
2021
Q2 		$5.23M Hold
26,820
– – 1.3% 24
2021
Q1 		$6.93M Buy
+26,820
New +$7.05M 1.41% 23

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sio Capital Management's XFOR Position: Q4 2024 in Review

Sio Capital Management sold out of X4 Pharmaceuticals (XFOR) in Q4 2024, closing a stake of 43,450 shares — an estimated $872K sold.

Sio Capital Management first reported a position in XFOR in Q1 2021 and held it in 14 quarters. The position peaked at $6.93M in Q1 2021. 89 funds tracked by Wall St. Rank hold XFOR as of Q4 2024.

  • Sio Capital Management reported no remaining X4 Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Sio Capital Management sold 43,450 X4 Pharmaceuticals shares in Q4 2024, an estimated $872K.
  • Sio Capital Management first reported a position in X4 Pharmaceuticals in Q1 2021 and held it in 14 quarters.
  • Sio Capital Management's X4 Pharmaceuticals position peaked at $6.93M in Q1 2021.
  • 89 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q4 2024.

Based on Sio Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.